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Surveillance of Wisconsin Organisms for Trends 
in Antimicrobial Resistance and Epidemiology 
(SWOTARE): epidemiologic correlates for 2016 
surveillance isolates
ABSTRACT
Background: The Centers for Disease Control and Prevention advocate data collection and 
monitoring as one facet of a comprehensive approach to combat antimicrobial resistance in 
the United States. However, a paucity of such data exists at the local/state level for common 
disease-causing organisms.
Methods: To begin to characterize epidemiologic correlates of antibacterial resistance in 
Wisconsin, data analyses were performed with respect to isolates in the Surveillance of 
Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) 
2016 collection. In addition to submitting isolates of Escherichia coli, Proteus mirabilis, 
Pseudomonas aeruginosa, and Streptococcus pneumoniae, participating laboratories were  
also requested to submit data regarding patient age, specimen source, and location of  
patient service.
Results: Fifty-five percent of isolates were of outpatient origin (including emergency 
department). In general, isolates derived from inpatients were more likely to demonstrate 
higher resistance rates than those from outpatient locations. Upon further stratification, 
isolates from emergency department encounters generally exhibited higher susceptibility 
rates than those from outpatient clinics. Sixty-seven percent of isolates emanated from 
skin and soft tissue or invasive sites. Delineation of specimen source played a minimal 
role in prediction of antimicrobial resistance. Older patients were more likely to generate 
isolates of E coli and P mirabilis exhibiting resistance to agents such as fluoroquinolones and 
trimethoprim-sulfamethoxazole.
Conclusions: SWOTARE facilitates epidemiologic investigations into resistance at the local/
state level. Investigations are warranted to further delineate differences in isolates derived 
from emergency department and outpatient clinic visits. Characterizations at the demographic 
level could impact local empiric treatment guidelines and antimicrobial stewardship 
throughout Wisconsin.
ORIGINAL  RESEARCH
T he Centers for Disease Control and Prevention (CDC) have recently identified 17 groupings of bacterial and 
fungal organisms collectively responsible for at least two million 
annual illnesses and 23 000 deaths on the basis of antimicrobial 
resistance.1 CDC has additionally advocated a 4 faceted approach 
to address the paradigm of national antimicrobial resistance, 1 of 
which involves timely surveillance for the emergence of novel and 
unique patterns of resistance. The value of such surveillance efforts 
has been championed by pioneers in the field.2
We have described implementation of the Surveillance of 
Wisconsin Organisms for Trends in Antimicrobial Resistance and 
Epidemiology (SWOTARE) program.3 In summary, a centralized 
microbiology laboratory assesses representative bacterial isolates 
using a standardized antimicrobial susceptibility testing method. 
These isolates are submitted by 22 clinical laboratories with 
widespread distribution throughout Wisconsin. With such 
infrastructure, we currently have capability of monitoring 3 of 
the CDC-targeted organism groups.1 Two of these, multidrug-
resistant Pseudomonas aeruginosa and drug-resistant Streptococcus 
pneumoniae, are responsible for 51 000 healthcare-associated 
infections4 and 4 million general infections,5 respectively, on an 
annual basis. These infections further translate into resistance rates 
approximating 13% to 30%,5,6 with annual deaths attributable 
to resistant strains estimated at 440 (P aeruginosa)7 and 7000 
(S pneumoniae).5 Furthermore, collected Escherichia coli can be 
monitored for evidence of carbapenemase and extended-spectrum 
β-lactamase (ESBL) production. It is estimated that these 
resistance mechanisms are responsible for greater than 10 000 
healthcare-associated infections in the United States annually, with 
approximately 700 attributable deaths.4,6-8
An additional component of the SWOTARE program involves 
submission of isolate-specific epidemiologic data from participating 
clinical laboratories. Such data may not be readily available in 
the course of surveillance endeavors strictly involving analysis 
of antibiogram data.9 Moreover, as part of the CDC-advocated 
surveillance approach,1 it is recommended that data be collected 
with respect to risk factors for antimicrobial resistance. This report 
provides introductory information relative to the epidemiology of 
antimicrobial resistance in Wisconsin, as generated by the 2016 
SWOTARE collection.
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METHODS
SWOTARE Program
Establishment of the SWOTARE surveillance network, along 
with isolate submission and susceptibility testing protocols/
interpretation,10 has been described.3 In summary, clinical 
microbiology laboratories in Ashland, Spooner, St. Croix Falls, and 
Eau Claire (northwest region); Marshfield, Weston, and Stevens 
Point (northcentral region); Manitowoc, Sturgeon Bay, and Green 
Bay (northeast region); Platteville, Prairie du Chien, Viroqua, 
and La Crosse (southwest region); Fort Atkinson, Janesville, 
and Madison (southcentral region); Fond du Lac, Neenah, 
and Appleton (Lake Winnebago region); and, West Bend and 
Milwaukee (southeast region) participated in the program.
Isolates and Demographic Data
Study sites were requested to collect consecutive isolates 
of E coli, Proteus mirabilis, P aeruginosa, and S pneumoniae 
identified from in-house culture of clinically significant infection. 
Laboratories were further requested to supply limited patient 
demographic information, including age, sex, anatomic source, 
patient service location, and whether the healthcare encounter 
involved an intensive care unit stay. Access to protected health 
information for the purpose of the investigation was granted by 
the Marquette University Institutional Review Board. Because of 
the lack of direct involvement in the collection of specimens and 
because of the utilization of de-identified isolates from routine 
clinical care, the Review Board did not consider the SWOTARE 
program to be actively engaged in human subjects research.
Data Analysis
Genus-specific percentage susceptible, intermediate 
(susceptible-dose dependent for cefepime and Enterobacteriaceae 
combinations11), and resistant values, as well as minimum inhibitory 
concentration (MIC) determinations (MIC₅₀ and MIC₉₀) were 
generated. Such analyses were applied to statewide isolates as 
a whole, in addition to characterizations on the basis of patient 
healthcare encounter location, specimen source, and patient age. 
Only patient service location, specimen source, and age delineations 
with n ≥ 25 were utilized for comparisons. The significance test of 
proportions determined if differences in susceptibility percentage 
were significant. The α level was set at .05 before the investigations 
commenced, and all P values are 2-tailed.
RESULTS AND EPIDEMIOLOGIC DISCUSSION
Patient Demographics and Isolate Distribution by 
Patient Location
One thousand eighty isolates were submitted to the program 
and tested in 2016. Of this total, complete demographic data 
were provided for 1055 (97.7%) isolates. Five hundred sixty-one 
(53.2%) isolates were derived from women. Mean patient age 
was 62.5 years, with a median of 66. Six general patient service 
categories (Figure 1) accounted for 94.8% of all patient isolates. 
As a result of the inclusion of data from long-term care facilities 
as inpatient data, the percentage composition of inpatient isolates 
was 45.4%, the largest component of which was internal medicine 
(25.6% of all isolates). Outpatient data consisted of outpatient 
clinic–derived isolates (30.0% of all isolates) and those collected 
from emergency departments (24.6% of all isolates).
Isolate Distribution by Specimen Source
Greater than two-thirds of specimens submitted to the 
SWOTARE program in 2016 were of skin and soft tissue or 
invasive origin (Figure 2). Invasive isolates included those derived 
from blood (354 isolates), cerebrospinal fluid (4), paracentesis 
fluid (1), hardware (1), bone (1) and bile (1). Sixteen percent of 
isolates were derived from urogenital (172 urine, 1 Bartholin cyst) 
sources. Distribution of lower respiratory tract isolates (12.6% of 
all isolates) included sputum (111), bronchoalveolar lavage (8), 
endotracheal aspiration (7), bronchial washings (6), thoracentesis 
fluid (3), and pleural fluid (1). Upper respiratory tract isolates 
included those derived from ear (18 isolates), nose (9), throat (8), 
eye (7), and sinus (4) specimens.
Profile by Patient Location
We compared differences in susceptibility rates for antimicrobial/
organism combinations as a function of patient care location 
from which the isolate was derived. Table 1A demonstrates one 
example of inpatient isolates exhibiting an increased antimicrobial 
Figure 1. Distribution of isolates assessed by the 2016 SWOTARE 
program, delineated by healthcare location of specimen collection.
Figure 2. Distribution of isolates assessed by the 2016 SWOTARE 
program, delineated by specimen source. 
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resistance profile over that of outpatient isolates. This inpatient 
P mirabilis profile is characterized by a decreased levofloxacin 
percentage susceptible value, as well as an elevated MIC₉₀ 
value. Further subcategorization of this antimicrobial/organism 
paradigm is represented in Table 1B. The frank resistance rates and 
increased MIC₉₀ values within this profile, as well as a majority 
of other antimicrobial/organism profiles (data not illustrated), 
justify inclusion of long-term care facilities with inpatient data. 
Initial insight into differences in susceptibility between isolates 
derived from emergency department visits (95.6% susceptibility) 
and those from internal medicine and outpatient clinic encounters 
(67.2% and 86.2%, respectively) was also observed.
On the basis of achieved n values, subsequent analysis was 
restricted to internal medicine, emergency department, and 
outpatient clinics. Greater than 61% of individual E coli, 
P mirabilis, P aeruginosa, and S pneumoniae/antimicrobial 
combinations revealed susceptibility rates that differed by less 
than 10% between the 3 healthcare locations (data not illustrated). 
Noteworthy exceptions included a cefazolin susceptibility 
difference of 16.1% between emergency department and internal 
medicine E coli isolates and a penicillin susceptibility difference 
of 22.1% between emergency department and internal medicine 
S pneumoniae isolates.
The potential influence of patient service location on 
empiric regimen choice is demonstrated in Table 2. For each 
of the 4 organisms investigated in the surveillance program, a 
higher proportion of antimicrobials demonstrated greater in 
vitro potency on emergency department–derived isolates when 
compared with outpatient clinic- and internal medicine–derived 
isolates. This dichotomy was especially noted with S pneumoniae, 
as 92.3% of antimicrobial/emergency department–derived isolate 
combinations demonstrated most in vitro potency when compared 
with internal medicine- and outpatient clinic–derived isolates 
(7.7% and 0%, respectively).
Studies attempting to associate increased antimicrobial 
resistance with patient service location have often been performed 
in the context of urinary tract infection. In general, healthcare-
Table 1. MIC0 and MIC Distributions and Categorical Interpretations of Proteus mirabilis Isolate Susceptibility to Levofloxacin by A: Inpatient 
and Outpatient and B: Most Prevalent Patient Locations, Wisconsin 2016
A
CLSI Breakpoints 2/4/8
Location n MIC MIC Susceptible Intermediate Resistant
Outpatient  
Inpatient 
Wisconsin
155 
116 
≤0.25
≤0.25
≤0.25
4
>32
16
89.0
69.0
81.0
1.9
3.4
2.5
9.1
27.6
16.5
B
CLSI Breakpoints 2/4/8
Location n MIC MIC Susceptible Intermediate Resistant
Clinics
Internal Medicine
Emergency Department
Intensive Care Unit
Long-term Care
Surgery
Wisconsin
109
64
46
10
23
13
≤0.25
≤0.25
≤0.25
0.5
2
≤0.25
≤0.25
16
>32
1
8
>32
32
16
86.2
67.2
95.6
70.0
65.2
92.3
81.0
1.8
4.7
2.2
10.0
0.0
0.0
2.5
11.9
28.1
2.2
20.0
34.8
7.7
16.5
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
Table 2. Frequency of Antimicrobial/Organism Testing Combinations 
Yielding Highest Percentage-Susceptible Values Compared by 
Location of Patient Encounter, Wisconsin 2016 a
Patient Encounter Location
Organism
Outpatient 
Clinic
Internal 
Medicine
Emergency 
Department
Escherichia coli 18.8 31.3 50.0
Proteus mirabilis 42.9 0.0 92.9
Pseudomonas  
aeruginosa 44.4 11.1 55.6
Streptococcus 
pneumoniae 0.0 7.7 92.3
a  Cumulative values may not equal 100% due to rounding or to 
multiple patient locations sharing highest percentage-susceptible 
value.
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associated urinary tract pathogens possess increased resistance 
rates when compared with community-acquired agents of urinary 
tract infection (particularly with respect to E coli resistance to 
fluoroquinolone agents). Examples of such data emanate from 
large study collections in international centers that are derived from 
antibiogram data12,13 or from surveillance programs.14 From a 4-year 
Swiss antibiogram study, Lamoth et al15 reported that community-
acquired strains of E coli and P aeruginosa (irrespective of specimen 
source) demonstrated higher susceptibility rates when compared to 
hospital-acquired strains. With respect to P aeruginosa, this group 
further implied that differences in ciprofloxacin and ceftazidime 
susceptibility were a function of specific inpatient unit. 
Additional investigations have focused on emergency 
department populations. Zatorski et al16 compared E coli 
antibiograms from non-intensive care unit inpatient urine cultures 
with those derived from emergency department patients and 
found increased ceftriaxone and ciprofloxacin susceptibility rates 
in the latter demographic. Draper et al17 used an antibiogram 
approach to determine that emergency department–derived E coli 
isolates (regardless of specimen source) demonstrated increased 
susceptibility rates to ampicillin, levofloxacin, and trimethoprim-
sulfamethoxazole when compared with hospital-wide isolates. A 
similar paradigm was observed with P aeruginosa and aztreonam.
Profile by Specimen Source
Differences in susceptibility rates were also compared on basis 
of specimen source. With respect to each organism, source-specific 
n values allowed comparisons among 3 specimen sources. Greater 
Table 4. MIC0 and MIC Distributions and Categorical Interpretations of Escherichia coli Isolate Susceptibility to A: Levofloxacin, and B: 
Trimethoprim-Sulfamethoxazole by Age, Wisconsin 2016
A
CLSI Breakpoints 2/4/8
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
40 
68 
159 
90 
≤0.25  
≤0.25
≤0.25
≤0.25
≤0.25
0.5  
16
32
16
16
92.5  
80.9
74.8
78.9
79.9
0.0  
0.0
0.0
0.0
0.0
7.5 
19.1
25.2
21.1
20.1
P = .02 for susceptibility rate of 20-39 years versus 60-79 years.
P = .06 for susceptibility rate of 20-39 years versus ≥80 years.
B
CLSI Breakpoints 2/4
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
40
68
159
90
≤1
≤1
≤1
≤1
≤1
>16
>16
>16
>16
>16
82.5
85.3
80.5
77.8
80.7
17.5
14.7
19.5
22.2
19.3
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
Table 3. Frequency of Percentage Susceptibility Value Differences for 
Combinations of Organisms and Antimicrobial Agents Compared by 
Top 3 Specimen Sources, Wisconsin 2016 a
Maximum  
Percentage-Susceptible Difference
Organism <5% 5-10% 10-20% >20%
Escherichia coli b 38.9 61.1 0.0 0.0
Proteus mirabilis c 72.2 16.7 5.6 5.6
Pseudomonas  
aeruginosa d 55.6 22.2 22.2 0.0
Streptococcus 
pneumoniae e 33.3 53.3 13.3 0.0
a  Individual specimen source (skin and soft tissue, invasive, 
urogenital, lower respiratory, upper respiratory) required 25 isolates 
to qualify for this analysis.
b  Top 3 specimen sources were invasive, skin and soft tissue, and 
urogenital.
c  Top 3 specimen sources were skin and soft tissue, urogenital, and 
invasive.
d  Top 3 specimen sources were skin and soft tissue, invasive, and 
lower respiratory.
e  Top 3 specimen sources were invasive, lower respiratory, and upper 
respiratory.
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than 86% of individual E coli, P mirabilis, and S pneumoniae/
antimicrobial combinations exhibited susceptibility rates that 
varied by <10% between specimen source (Table 3). In contrast, 
22.2% of P aeruginosa/antimicrobial combinations involved 
susceptibility variation of >10% between specimen sources. 
This was characterized by increased meropenem and aztreonam 
susceptibility rates for invasive P aeruginosa isolates (data not 
illustrated).
In essence, influence of specimen source on potential empiric 
regimen choice was less pronounced than that described for 
location of patient encounter. As one example, urogenital isolates 
predicted a marginally greater proportion of highly susceptible 
antimicrobial agents for P mirabilis (50.0%) when compared 
with skin and soft-tissue isolates (35.7%; data not illustrated). 
Although participating laboratories were asked to focus collection 
efforts on isolates derived from skin and soft tissue, invasive, 
and lower respiratory tract sources, lower-volume laboratories 
on occasion submitted urinary tract isolates to the SWOTARE 
program to fulfill an organism quota. The aforementioned analyses 
(ie, marginal susceptibility differences among specimen sources) 
suggest that inclusion of this additional specimen source had 
minimal impact on regional susceptibility rates and contributed to 
overall representative sampling within the geographic area.
Profile by Patient Age
Finally, age-related determinants of antimicrobial resistance for 
each of the 4 surveillance organisms were investigated by focusing 
on the 2 to 3 antimicrobial agents with the lowest percentage-
susceptible values, as elucidated in a previous report.3 E coli isolates 
derived from 20- to 39-year-olds demonstrated more susceptibility 
to levofloxacin than those from 60- to 79-year-olds (P = .02; Table 
4A). These isolates also trended toward greater susceptibility when 
compared with those from patients aged ≥ 80 years (P = .06). 
No age-related relationships were noted with trimethoprim-
sulfamethoxazole (Table 4B) and ampicillin susceptibility.
With respect to P mirabilis, isolates derived from patients aged 
20 to 39 years yielded increased rates of ciprofloxacin susceptibility 
when compared with isolates from patients aged 60 to 79 years 
and ≥ 80 years (P = .04 and P = .02, respectively; Table 5A). 
Similarly, P mirabilis isolates from 20- to 39-year-old patients 
exhibited increased trimethoprim-sulfamethoxazole susceptibility 
when compared with all other age groups (P ≤ .04; Table 5B). No 
significant differences were noted when ampicillin susceptibility 
was stratified by patient age.
P aeruginosa isolates from 40- to 59-year-old patients exhibited 
decreased ciprofloxacin susceptibility when compared with patients 
over the age of 60 years (P ≤ .03; Table 6A). Similarly, P aeruginosa 
Table 5. MIC0 and MIC Distributions and Categorical Interpretations of Proteus mirabilis Isolate Susceptibility to A: Ciprofloxacin, and B: 
Trimethoprim-Sulfamethoxazole by Age, Wisconsin 2016
A
CLSI Breakpoints 1/2/4
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
25
60
110
71
≤0.25  
≤0.25
≤0.25
≤0.25
≤0.25
1
16
32
32
32
92.0
80.0
72.7
67.6
75.6
0.0
1.7
3.6
8.5
4.3
8.0
18.3
23.6
23.9
20.1
P = .04 for susceptibility rate of 20-39 years versus 60-79 years.
P = .02 for susceptibility rate of 20-39 years versus ≥80 years.
B
CLSI Breakpoints 2/4
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
25
60
110
71
≤1
≤1
≤1
≤1
≤1
≤1
>16
>16
>16
>16
100
85.0
77.3
80.3
82.4
0.0
15.0
22.7
19.7
17.6
P = .04 for susceptibility rate of 20-39 years versus 40-59 years.
P = .008 for susceptibility rate of 20-39 years versus 60-79 years.
P = .02 for susceptibility rate of 20-39 years versus ≥80 years.
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
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isolates derived from patients aged 60 to 79 years demonstrated 
less susceptibility to aztreonam than isolates from patients aged 
≥ 80 years (P = .05; Table 6B). No significant age delineations were 
determined with respect to S pneumoniae susceptibility to either 
penicillin (P ≥ .22; Table 7A) or erythromycin (P ≥ .18; Table 7B). 
Swami and Banerjee18 used an antibiogram approach to stratify 
antimicrobial resistance patterns in E coli and S pneumoniae by 
patient age (< 18 years; 18-64 years; ≥ 65 years) at a United States 
institution. The authors noted that their institution-wide 
antibiogram underestimated resistance profiling in older patients 
(particularly with respect to ciprofloxacin and E coli) when 
compared with a specialized antibiogram devised for populations 
aged ≥ 65 years. In a European study, Grignon et al19 reported 
a risk factor for increased ciprofloxacin resistance in emergency 
department E coli isolates as being age ≥ 45 years. Data presented in 
tables 4 through 7 used an isolate-based approach (stratified over an 
increased number of age groupings) to corroborate these findings. 
In addition, we were able to extend this paradigm to an additional 
member of Enterobacteriaceae (Table 5) with another antimicrobial 
class (trimethoprim-sulfamethoxazole; Table 5B). Swami and 
Banerjee18 also reported decreased S pneumoniae susceptibility to a 
number of antimicrobial classes in pediatric populations. We were 
unable to analyze SWOTARE data for a comparative phenomenon 
at this time due to low n values for patients under the age of 20 
years. Other S pneumoniae comparisons throughout this study 
were limited to an extent by disproportionate isolate contributions 
across a number of geographic regions.3 Increased isolate quota 
in future surveillance collections will improve the validity of 
antimicrobial-resistant S pneumoniae epidemiologic findings.
In addition to the demographic factors affecting antimicrobial 
resistance that are described in this report, one cannot discount 
the contribution of geographic location. In the context of the 
2016 SWOTARE collection, several geographic paradigms were 
noted.3 Grignon et al19 investigated E coli antimicrobial resistance 
in the emergency department setting in a region of France 
(with population of 3.6 million) with an area equivalent to the 
state of Maryland. Of 10 participating emergency departments, 
5 were specifically cited as significant risk factors for increased 
fluoroquinolone resistance in uropathogenic E coli. 
In discussing the current status of antimicrobial resistance 
in the United States, the CDC cited gaps in general knowledge 
that involved limited national and state capacity for the detection 
of emerging antimicrobial resistance trends.1 Past state-based 
efforts,20,21 as well as those described within the context of the 
SWOTARE program, are therefore necessary to supplement 
data generated by national programs. Moreover, the SWOTARE 
program already possesses the infrastructure to allow for both 
annual assessment of resistance trending and a broadening of 
scope via introduction of additional organism groups into the 
surveillance paradigm. Boucher et al22 listed a number of pathogens 
(vancomycin-resistant Enterococcus faecium, methicillin-resistant 
Staphylococcus aureus, ESBL-producing Klebsiella spp. and E coli, 
carbapenemase-producing Klebsiella spp., Acinetobacter baumannii, 
P aeruginosa, and Enterobacter spp.) for which antimicrobial agent 
Table 6. MIC0 and MIC Distributions and Categorical Interpretations of Pseudomonas aeruginosa Isolate Susceptibility to A: Ciprofloxacin, and 
B: Aztreonam by Age, Wisconsin 2016
A
CLSI Breakpoints 1/2/4
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
17
48
86
48
 
≤0.25  
≤0.25
≤0.25
≤0.25
≤0.25
0.5
8
2
1
2
94.1
77.1
90.7
93.8
88.2
0.0
8.3
2.3
0.0
3.3
5.9
14.6
7.0
6.3
8.5
P = .03 for susceptibility rate of 40-59 years versus 60-79 years.
P = .02 for susceptibility rate of 40-59 years versus ≥80 years.
B
CLSI Breakpoints 8/16/32
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
17
48
86
48
8
4
8
4
8
8
32
16
16
16
94.1
77.1
75.6
89.6
81.0
5.9
10.4
17.4
6.3
12.3
0.0
12.5
7.0
4.2
6.6
P = .05 for susceptibility rate of 60-79 years versus  ≥80 years. 
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
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research and development efforts have become 
increasingly necessary. Before such advancements 
are made, close surveillance of currently available 
agents is essential. The SWOTARE program 
currently allows for statewide monitoring of 3 
of the 7 aforementioned ESKAPE pathogens in 
Wisconsin, as well as 1 additional pathogen cited by 
the World Health Organization as another focus for 
development of alternative antimicrobial strategies.23
CONCLUSIONS
A number of approaches have been considered in 
the monitoring of antimicrobial resistance patterns. 
One advantage of a surveillance paradigm based on 
isolate collection, such as the SWOTARE program, is 
its capability of ascribing demographic information 
to isolates. Testing within the SWOTARE program 
in 2016 revealed resistance variation with respect to 
a number of antimicrobial/organism combinations. 
These differences were more relative to location of 
patient encounter and patient age when compared 
with specimen source. Year 1 of this surveillance 
project also revealed particular niches of potential 
emerging resistance that will be assessed in future 
seasons of isolate collection. All told, provision of 
these data to a broad audience may potentiate revision 
of local empiric therapy guidelines and contribute to 
antimicrobial stewardship efforts.
Table 7. MIC0 and MIC Distributions and Categorical Interpretations of Streptococcus pneumoniae Isolate Susceptibility to A: Penicillin, and  
B: Erythromycin by Age, Wisconsin 2016
A
CLSI Breakpoints 0.06/0.12*
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
23
37
72
44
 
≤0.015
≤0.015
≤0.015
≤0.015
≤0.015
0.25
2
0.5
1
1
60.9
75.7
72.2
68.2
70.3
39.1
24.3
27.8
31.8
29.7
B
CLSI Breakpoints 0.25/0.5/1
Age, y n MIC MIC Susceptible Intermediate Resistant
20-39  
40-59 
60-79 
≥80 
Wisconsin
23
37
72
44
≤0.06
≤0.06
2
≤0.06
≤0.06
>4
>4
>4
>4
>4
52.2
62.2
48.6
52.3
54.2
0.0
0.0
0.0
0.0
0.0
47.8
37.8
51.4
47.7
45.8
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
*Breakpoints for meningeal S pneumoniae isolates.
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